{"nctId":"NCT00568178","briefTitle":"An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))","startDateStruct":{"date":"2007-06-01","type":"ACTUAL"},"conditions":["Proteinuria"],"count":306,"armGroups":[{"label":"Losartan Double-Blind Base Study (12-weeks)","type":"EXPERIMENTAL","interventionNames":["Drug: Losartan Potassium","Other: Comparator: Placebo (Losartan)"]},{"label":"Amlodipine Double-Blind Base Study (12-weeks)","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Comparator: Placebo (Losartan)","Drug: Comparator: amlodipine besylate","Other: Comparator: Placebo (amlodipine besylate)","Other: Placebo (Losartan)"]},{"label":"Losartan Open-Label Extension Phase (Month 36)","type":"EXPERIMENTAL","interventionNames":["Drug: Losartan Potassium"]},{"label":"Enalapril Open-Label Extension Phase (Month 36)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enalapril Maleate"]}],"interventions":[{"name":"Losartan Potassium","otherNames":["Cozaar®"]},{"name":"Comparator: Placebo (Losartan)","otherNames":[]},{"name":"Comparator: amlodipine besylate","otherNames":["NORVASC®"]},{"name":"Comparator: Placebo (amlodipine besylate)","otherNames":["NORVASC®"]},{"name":"Placebo (Losartan)","otherNames":[]},{"name":"Enalapril Maleate","otherNames":["Vasotec®","Renitec®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant is 1 to 17 years of age\n* Able to provide a first-morning urine sample each day during the study\n* Documented history of proteinuria associated with chronic kidney disease of any origin\n* Signed consent of parent and/or legal guardian\n\nExclusion Criteria:\n\n* Pregnant and/or nursing\n* Requires more than 2 medications to control high blood pressure\n* Has undergone major organ transplantation (e.g. heart, kidney, liver)\n* Known sensitivity to losartan or other similar drugs, or any history of angioneurotic edema\n* Known sensitivity to amlodipine or other calcium channel blocker\n* Requires cyclosporine to treat renal disease (kidney disease)","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Months","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12","description":"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\\*, after approximately twelve weeks of treatment.\n\nBaseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.80","spread":null},{"groupId":"OG001","value":"1.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":null},{"groupId":"OG001","value":"-0.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36","description":"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline\\*, after approximately three years of treatment.\n\n\\*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.01","spread":"5.02"},{"groupId":"OG001","value":"-40.45","spread":"2.10"}]}]}]},{"type":"PRIMARY","title":"Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36","description":"The outcome measure of glomerular filtration rate was based on mL/min/1.73m\\^2, as determined by the Schwartz formula:\n\nGFR = \\_\\_\\_\\_\\_0.55 x height (cm)\\_\\_\\_\\_\\_\\_\\_ divided by serum creatinine (mg/dL)\n\nGFR values were compared to the baseline GFR measure.\n\n\\[Note: For male participants, ages 13 to 17 years, 0.70 was used as\n\nthe multiplier in place of 0.55\\]\n\nBaseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"66.3"},{"groupId":"OG001","value":"7.0","spread":"53.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":152},"commonTop":["Nasopharyngitis","Pharyngitis","Headache","Upper respiratory tract infection","Bronchitis"]}}}